Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
- PMID: 38604986
- DOI: 10.1111/bcp.16067
Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
Abstract
Aims: While diagnostic codes from administrative health data might be a valuable source to identify adverse drug events (ADEs), their ability to identify unintended harms remains unclear. We validated claims-based diagnosis codes for ADEs based on events identified in a prospective cohort study and assessed whether key attributes predicted their documentation in administrative data.
Methods: This was a retrospective analysis of 3 prospective cohorts in British Columbia, from 2008 to 2015 (n = 13 969). We linked prospectively identified ADEs to administrative insurance data to examine the sensitivity and specificity of different diagnostic code schemes. We used logistic regression to assess which key attributes (e.g., type of event, symptoms and culprit medications) were associated with better documentation of ADEs in administrative data.
Results: Among 1178 diagnosed events, the sensitivity of the diagnostic codes in administrative data ranged from 3.4 to 52.6%, depending on the database and codes used. We found that documentation was worse for certain types of ADEs (dose-related: odds ratio [OR]: 0.32, 95% confidence interval [CI]: 0.15, 0.69; nonadherence events (OR: 0.35, 95% CI: 0.20, 0.62), and better for those experiencing arrhythmias (OR: 4.19, 95% CI: 0.96, 18.28).
Conclusion: ADEs were not well documented in administrative data. Alternative methods should be explored to capture ADEs for health research.
Keywords: administrative data; adverse drug event; adverse drug reaction; drug safety; pharmacovigilance.
© 2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Similar articles
-
Re-Exposure to Culprit Medication Following Adverse Drug Event Diagnosis in Canadian Emergency Department Patients: A Cohort Study.Pharmacoepidemiol Drug Saf. 2024 Sep;33(9):e70012. doi: 10.1002/pds.70012. Pharmacoepidemiol Drug Saf. 2024. PMID: 39300754
-
Use of ICD-10-CM T codes in hospital claims data to identify adverse drug events in Taiwan.J Clin Pharm Ther. 2021 Apr;46(2):476-483. doi: 10.1111/jcpt.13308. Epub 2020 Nov 18. J Clin Pharm Ther. 2021. PMID: 33210301
-
Detection of adverse drug events in e-prescribing and administrative health data: a validation study.BMC Health Serv Res. 2021 Apr 23;21(1):376. doi: 10.1186/s12913-021-06346-y. BMC Health Serv Res. 2021. PMID: 33892716 Free PMC article.
-
Capture and documentation of coded data on adverse drug reactions: an overview.Health Inf Manag. 2012;41(3):27-36. doi: 10.1177/183335831204100304. Health Inf Manag. 2012. PMID: 23705134 Review.
-
Establishing a trigger tool based on global trigger tools to identify adverse drug events in obstetric inpatients in China.BMC Health Serv Res. 2024 Jan 15;24(1):72. doi: 10.1186/s12913-023-10449-z. BMC Health Serv Res. 2024. PMID: 38225629 Free PMC article. Review.
Cited by
-
ICD-10 Codes to Identify Adverse Drug Events Associated with Antibiotics in Administrative Data.Antibiotics (Basel). 2025 Mar 18;14(3):314. doi: 10.3390/antibiotics14030314. Antibiotics (Basel). 2025. PMID: 40149123 Free PMC article.
-
Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes.Drug Saf. 2023 Nov;46(11):1161-1172. doi: 10.1007/s40264-023-01348-7. Epub 2023 Oct 2. Drug Saf. 2023. PMID: 37783974 Free PMC article.
References
REFERENCES
-
- Hohl CM, Badke K, Zhao A, et al. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Acad Emerg Med. 2018;25(9):1015‐1026. doi:10.1111/acem.13407
-
- Zed PJ, Abu‐Laban RB, Balen RM, et al. Incidence, severity and preventability of medication‐related visits to the emergency dep0061rtment: a prospective study. CMAJ. 2008;178(12):1563‐1569. doi:10.1503/cmaj.071594
-
- Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost‐effectiveness of warfarin: Trial versus “real‐world” stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064‐1073. doi:10.1016/j.ahj.2009.03.022
-
- Staa T‐P, Leufkens HG, Zhang B, Smeeth L. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective Cox‐2 inhibitors as an example. PLoS Med. 2009;6(12):e1000194. doi:10.1371/journal.pmed.1000194
-
- Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2016;35(36):185‐198. doi:10.1200/EDBK_156686
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical